Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

NCT02857920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: Bevacizumab
BIOLOGICAL: NK immunotherapy

Sponsor

Fuda Cancer Hospital, Guangzhou

Collaborators

[object Object]